With the nation at war for eight continuous years, and awareness of the dangers of sports concussions on the rise, a new priority—and opportunity—are taking shape for neurodegenerative disease researchers. In a time of austere budgets, the Department of D
Cerebrospinal Fluid Tau Climbs in Aβ Mouse Models Coverage Denial For Amyloid Scans Riles Alzheimer’s Community Pooled GWAS Reveals New Alzheimer’s Genes and Pathways Are Subtle Memory Concerns a Sign of Future Dementia? Clinical Trials Roundup: Four Hits
Experimental α7 Agonist Meets Cognitive and Clinical Endpoints New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity Q&A With Roche’s CNS Leader Luca Santarelli When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion? Wave of Ne
Madrid: ICAD Conference Draws to a Close Madrid: BACE Found to Have Big Job in Wrapping Motoneurons Madrid: Why Do People Drop Out of Trials? Madrid: Stressed Brain—SNP Carriers Can Have Cake and Eat It Madrid: BACE News Roundup, Part 1 Madrid: BACE News
Philadelphia: All Eyes on PIB Imaging—Is It Coming Along? Philadelphia: All Is Not Well with the Statin Story Philadelphia: Can a Shrinking Brain Be Good for You? Philadelphia: Dementia Types Just Won’t Fit into Little Boxes Philadelphia: Diagnosis Light—
Stockholm: Visualizing Amyloid Biggest Draw at Imaging Symposium, Consensus Sought on Validation Stockholm: Chlamydia Triggers Amyloid Plaques in Mice Stockholm: Aph-1 and Pen-2: New Names in the Presenilin Debate Complete the Complex? Stockholm: Clusteri
Washington: Alzhemed Non-story Yields Spotlight to Phase 2 Treatments Washington: Shaking Up AD Treatment with Ketone Bodies Washington: Site-to-Site Differences Delay Result of Alzhemed Trial Washington: γ-secretase Inhibitor Survived Phase 2, Moving to
Chicago: Studies Probe Diminishing Placebo Decline, Part 1 Chicago: Studies Probe Diminishing Placebo Decline, Part 2 Chicago: ICAD Offered Mix Bag of Setbacks and Hopeful News Chicago: Trial Design Bedevils Search for New AD Drugs, Part 1 Chicago: The Ph
Vienna: New Genes, Anyone? ICAD Saves Best for Last Vienna: In Genetics, Bigger Is Better—Data Sharing Nets Three New Hits Vienna: Can a D-Peptide Turn Tiger Into Pussycat? Vienna: New Shoot Among Ashes of Drug Trials Vienna: New Tack to See Amyloid Oligo
Honolulu: FDA Approval in Sight for 18F Amyloid Tracer Florbetapir? Honolulu: Tomm40 Reported to Track With Brain Atrophy, Cognition Honolulu: TrialMatch Launched as AD Is Becoming “Desktop” Disease Honolulu: The Missing Link? Tau Mediates Aβ Toxicity at
Paris: Renamed ARIA, Vasogenic Edema Common to Anti-Amyloid Therapy Paris: Semagacestat Autopsy and Other News of Trial Tribulations Paris: More Trial News, Mixed at Best Paris: President and All, French Science Takes the Stage Paris: Beyond Genomics, Fre
Sixth Int. Conference on AD: Mechanisms of Neurodegenerative Conditions I Sixth Int. Conference on AD: Genetics I Sixth Int. Conference on AD: Monkey Brain Injections Sixth Int. Conference on AD: Cellular/Animal Models I Sixth Int. Conference on AD: Mecha
1998 Society for Neuroscience Meeting: α2-Macroglobulin 1998 Society of Neuroscience Meeting: AD Plaques Associated with Curvier Dendrites 1998 Society for Neuroscience Meeting: Aβ vs. APP Effects in Transgenics 1998 Society for Neuroscience Meeting: Fram
Society for Neuroscience Annual Meeting: β-Secretase Further Confirmed Society for Neuroscience Annual Meeting: Another APP Secretase? Society for Neuroscience Annual Meeting: Imaging Amyloid Plaques in the Living Mouse Soc for Neuroscience Ann Mtg: One γ
Society for Neuroscience Annual Meeting: Stem Cells Drawn to Aβ Society for Neuroscience Annual Meeting: Stem Cells Promising for Motor Neuron Disorders Society for Neuroscience Annual Meeting: Does ApoE Contribute to Tangle Formation? Society for Neurosc